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Abstract
Summary We evaluated the longitudinal effects of anti-
resorptive agents (534 treated women vs. 1,150 untreated)
on lumbar spine bone mineral density (BMD) and trabecular
bone score (TBS). TBS was responsive to treatment in
women over age 50. The treatment-related increase in TBS
was less than the increase in BMD, which is consistent with
bone texture preservation.
Introduction In addition to inducing an increase in BMD,
anti-resorptive agents also help to preserve bone architecture.
TBS, a new gray-level texture measurement, correlates with
3D parameters of bone micro-architecture independent of
BMD. Our objective was to evaluate the longitudinal effects
of anti-resorptive agents on lumbar spine BMD and TBS.
Methods Women (≥50 years), from the BMD program da-
tabase for the province of Manitoba, Canada, who had not
received any anti-resorptive drug prior to their initial dual
X-ray absorptiometry (DXA) exam were divided into two
groups: untreated, those without any anti-resorptive drug over
the course of follow-up, and treated, those with a non-
estrogen anti-resorptive drug (86 % bisphosphonates, 10 %
raloxifene, and 4 % calcitonin). Lumbar spine TBS was
calculated for each lumbar spine DXA examination.
Changes in TBS and BMD between baseline and follow-
up (mean follow-up 3.7 years), expressed in percentage per
year, were compared between the two groups.
Results A total of 1,150 untreated women and 534 treated
womenmet the inclusion criteria. Only a weak correlation was
seen between BMD and TBS in either group. Significant
intergroup differences in BMD change and TBS change were
observed over the course of follow-up (p<0.001). Similar
mean decreases in BMD and TBS (−0.36 %/year and
−0.31 %/year, respectively) were seen for untreated subjects
(both p<0.001). Conversely, treated subjects exhibited a sig-
nificant mean increase in BMD (+1.86 %/year, p<0.002) and
TBS (+0.20 %/year, p<0.001).
Conclusion TBS is responsive to treatment with non-estrogen
anti-resorptive drug therapy in women over age 50. The
treatment-related increase in TBS is less than the increase in
BMD, which is consistent with bone texture preservation.
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Introduction
Osteoporosis is a major health concern in virtually all indus-
trialized countries [1] due to the increased risk of fracture and
the associated morbidity and mortality associated with these
fractures, the mortality rate sometimes exceeding 20 % [2, 3].
Up to nine million new osteoporotic fractures are projected
worldwide each year [4]. Postmenopausal women are clearly
the demographic group at greatest risk. In the USA, osteopo-
rosis affects between four and six million postmenopausal
women [5]. Increases in the life spans of both males and
females are projected to double the magnitude of the osteo-
porosis problem over the next 40–50 years [6].
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Since 1994, bone mineral densitometry (BMD), as mea-
sured by dual X-ray absorptiometry (DXA), has been the gold
standard tool both for osteoporosis detection and the monitor-
ing of treatment efficacy [7]. Although bone density is one of
the major determinants of bone strength and fracture risk [8], a
considerable overlap exists in BMD values between individ-
uals who develop fractures and those who do not [9]. Other
factors that influence both bone strength and fracture risk
include the macro- and micro-architecture of the cortical bone
(including cortical porosity), micro-architecture and mineral-
ization of the trabecular bone, and bone turnover [10–12].
The trabecular bone score (TBS) is a novel gray-level
texture measurement that is able to differentiate between
individuals that exhibit the same bone density, but different
bone micro-architectural texture [13–16]. One way to
achieve this is to determine the variogram of the projected
bone image, calculated as the sum of the squared gray-level
differences between pixels at a specific distance and angle
[13–16]. In brief, TBS is calculated as the slope of the log–
log transform of this variogram. This slope characterizes the
rate of gray-level amplitude variations in the bone. TBS can
be applied retrospectively to an existing DXA exam, with-
out the need for any further imaging, and can therefore be
compared directly with BMD since both evaluate the same
region of the bone. In short, TBS is derived from the texture
of the DXA image and has been shown to be related to bone
micro-architecture and fracture risk.
The added value of the TBS in bone mineral densitome-
try for fracture risk assessment has been documented in
cross-sectional and longitudinal studies [17–25]. The objec-
tive of the current study was to assess the sensitivity of TBS
to detect change over time in a large cohort of treated versus
untreated older women.
Methods
Study population
In this retrospective cohort study, paired baseline and
follow-up DXA images of the lumbar spine, which had been
collected from a large clinical cohort of women (≥50 years)
in the Canadian province of Manitoba, were sent to the
University of Lausanne, Switzerland for the calculation of
TBS values. In addition to the actual gray-scale images,
further information collected for analysis through the Man-
itoba Bone Density Program included the following: (1)
demographic data; (2) clinical data, including diagnosed
fractures; and (3) BMD results, thereby allowing for the
calculation of baseline and follow-up BMD values for each
subject. The Manitoba Bone Density Program is a clinical
program based upon targeted case finding, as described
elsewhere [26–29]. The associated database exceeds 99 %
in terms of completeness and accuracy [29]. Our study
protocol was approved by both the Research Ethics Board
for the University of Manitoba and the Health Information
Privacy Committee of Manitoba Health.
To be eligible for the current study, women had to (1) be at
least 50 years of age; (2) have medical coverage from Man-
itoba Health over the entire course of the study observation
period; (3) have paired baseline and follow-up lumbar spine
DXA examinations, including BMD measurements of the
lumbar spine and hip, utilizing one of the program's three
cross-calibrated single narrow fan-beam scanners (Prodigy,
GE Healthcare, Madison, WI, USA); and (4) have not re-
ceived any hormone replacement therapy (HRT) or other
anti-resorptive drug prior to their baseline BMD assessment.
The average duration of follow-up was marginally shorter in
women who received treatment versus untreated women (3.6
vs. 3.8 years). We excluded anyone with >90 days of gluco-
corticoid use in the year before baseline DXA or in a single
year between the baseline and follow-up DXA.
A second database used for the study was Manitoba's
provincial pharmacy database system, a province-wide pro-
gram that records all retail prescriptions and drug dispensa-
tions, thereby allowing us to identify which women had
received treatment for osteoporosis as well as the drugs pre-
scribed and adherence rates. Using the data drawn from the
provincial pharmacy system, eligible women were divided
into two subgroups: (1) those who had not received any
HRT or anti-resorptive drug therapy over the period of time
between their baseline and follow-up DXA examination, des-
ignated as the “untreated” group; and (2) those who had
initiated a non-estrogen anti-resorptive drug and exhibited a
high level of treatment adherence (defined as a medication
possession ratio >75 %), designated as the “treated” group.
Measurement of BMD
All DXA scans had been performed and analyzed in the
province of Manitoba, in accordance with manufacturer
recommendations. BMD measurements were recorded for
the lumbar spine for L1 through L4 (L1–L4) and for the
femoral neck (and total hip). Hip T-scores were calculated
using the revised NHANES III Caucasian female reference
values [30, 31]. All scans were reprocessed centrally using
the same software (enCore version 12.0, GE Healthcare).
Values that fell below the 0.1 percentile or above the 99.9
percentile were treated as outliers and excluded from further
analysis. The resultant data approximated a normal distribu-
tion. The three instruments used in the study (all Prodigy, GE
Healthcare) were cross-calibrated using anthropomorphic
phantoms, and no clinically significant differences were iden-
tified (T-score differences <0.2). Therefore, all analyses are
based upon unadjusted numerical results generated by the
instrument. For 98 % of the subjects, the follow-up scan was
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performed on the same instrument as the baseline scan. No
magnification effects have been reported for the densitometer
used in this study [32, 33]. Instruments used in this study
exhibited stable long-term performance (coefficient of varia-
tion (CV) <0.5 %) and satisfactory in vivo precision [34].
Measurement of TBS
All TBS measurements were performed within the Bone
Disease Unit at the University Hospital of Lausanne, Lau-
sanne, Switzerland using TBS iNsight® software version
1.8.2 (Med-Imaps, Bordeaux, France). Each lumbar spine
DXA examination selected from the Manitoba database was
anonymized to ensure blinding to clinical parameters and
outcomes. Then, each lumbar spine raw DXA images were
uploaded into the TBS iNsight software. Lumbar spine TBS
was then evaluated using the patented algorithm in the same
regions of measurement as those used for the lumbar spine
BMD (mask of the region of interest and edge detection were
copied from the DXA scans), with lumbar spine TBS calcu-
lated as the mean value of the individual measurements for
vertebrae L1–L4. Short-term reproducibilities (CV) for TBS
calculated from the three instruments used in the Manitoba
study and thus from several technicians were 2.1 % and 1.7 %
for spine TBS and BMD, respectively, in 92 individuals with
repeat spine DXA scans performed within 28 days [23].
Statistical analysis
Descriptive analysis included means and percentages with
standard deviations. Annual percent change in BMD and
TBS was calculated for each subject as the absolute change
divided by the baseline value, and years of follow-up. Bivar-
iate intergroup comparisons were performed between those
treated and not treated with a non-HRT anti-resorptive drug
using Student's t tests and Pearson's χ2 analysis for contin-
uous and non-continuous variables, respectively. All statis-
tical analyses were performed using Statistica (version 8.0,
StatSoft, Inc., Tulsa, OK, USA). Given that there were four
outcomes of interest (percent annual changes in total hip,
femoral neck, and lumbar spine BMD, and lumbar spine
TBS), the Bonferroni-adjusted threshold for statistical sig-
nificance was set at p<0.01. All inferential tests were two-
tailed.
Results
The final sample consisted of 1,684 women: 534 treated and
1,150 untreated. At baseline, treated and untreated women
differed significantly in most characteristics that would favor
the initiation of osteoporosis treatment (Table 1). Treated
women averaged almost 4 years older (66.1±8.0 vs. 62.2±
7.9, respectively; p<0.001). Baseline lumbar spine BMD T-
score and TBS were all significantly lower in women who
were started on treatment (all p<0.001). Roughly one in six
women initiated on treatment had had a prior major osteopo-
rotic fracture (hip, clinical spine, forearm, or humerus) versus
one in ten untreated women (p00.009). Only weak correla-
tions were seen between baseline lumbar spine TBS and
lumbar spine BMD (r00.30, p<0.001), femoral neck BMD
(r00.23, p<0.001), and total hip BMD (r00.22, p<0.001),
which were of similar magnitude in subgroups stratified
according to treatment status (all p<0.001). Baseline BMD
therefore explained less than 10 % of the variance in lumbar
spine TBS. There were even weaker correlations between the
change in lumbar spine TBS and change in lumbar spine
BMD (r00.18, p<0.001), femoral neck BMD (r00.11,
p<0.001), and total hip BMD (r00.08, p<0.001). The corre-
lation between the change in lumbar spine TBS and lumbar
spine BMDwas significant in both untreated (r00.11, p<0.001)
and treated subgroups of women (r00.18, p<0.001) but
explained less than 5 % of the variance in change.
Of the different anti-resorptive drugs prescribed to the trea-
ted women, by far, the most common were bisphosphonates
(86 % of which, the majority (73 %) was alendronate); ralox-
ifene use (10 %) and calcitonin use (4 %) were much less
common. Over the course of follow-up, significant differences
in BMD change and TBS change were observed between those
treated and untreated (p<0.001); BMD and TBSmeasurements
increased significantly in women on treatment compared to
both baseline and the untreated group, but decreased signifi-
cantly in untreated women compared to both baseline and the
treated group (Table 2). Similar mean decreases in lumbar spine
BMD and TBS were seen among the untreated women com-
pared to the baseline (−0.36 % per year, 95 % confidence
interval (CI) −0.52 to −0.20 %; −0.31 % per year, 95 % CI
−0.48 to −0.15%) (Fig. 1). Conversely, a much greater increase
in lumbar spine BMD was observed among treated women
(+1.86 % per year, 95 % CI +1.71 to +2.02 %) than in lumbar
spine TBS (+0.20 % per year, 95 % CI +0.04 to +0.37 %).
When considering individuals, for detecting significant
decrease (below the least significant change) in untreated
subjects, BMD showed a slightly greater sensitivity than
TBS (24 vs. 18 %, McNemar test p00.0003). For detecting
significant increase (above the least significant change) in
treated subjects, as expected, BMD is much more sensitive
than TBS (54 vs. 12 %, p<0.0001).
Discussion
Previous studies have documented the value of the TBS in
assessing fracture risk in postmenopausal women [14–25].
The value of TBS for assessing risk is both sizeable and inde-
pendent of BMD, which makes sense given the increasing
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understanding of the importance of bone architecture in deter-
mining bone strength [1, 9–11, 35]. Indeed, TBS has been found
(1) to be lower in postmenopausal women with a past osteopo-
rotic fracture relative to age- and BMD-matched women with-
out fracture [17]; (2) to be associated with an incremental
increase in odds ratio for spine fracture when combined with
lumbar spine BMD [18–22]; (3) to be lower in women with
fractures, irrespective of whether their BMD meets the criteria
for osteoporosis or osteopenia [18–22]; (4) to prospectively
predict fracture as well as lumbar spine BMD [23–25]; and (5)
to capture roughly one third of misclassified fractures according
to the BMD WHO definition of osteoporosis alone [23–25].
In the current study, we sought to establish whether TBS is
useful for monitoring the effectiveness of anti-osteoporosis
therapy. First of all, the BMD response on anti-resorptive
drugs at all skeletal sites is in general agreement with pub-
lished treatment-related increases [36]. We observed that lum-
bar spine TBS, an index of bone micro-architectural texture,
does indeed increase significantly over time with treatment
and falls significantly without treatment, paralleling changes
in BMD. Interestingly, the magnitude of the decrease in lum-
bar spine TBS without treatment closely mimicked that of
BMD. The same cannot be said of the increases in lumbar
spine TBS and BMD on treatment, with the latter being almost
ten times greater. If one can prove that an increase of TBS
under treatment is associated with a fracture reduction (or the
reverse when TBS decrease), then it would make perfect sense
to use both BMD and TBS to monitor treatment or at least to
select the most appropriate drugs for a given patient. Unfor-
tunately, our current study has not been designed to support
such assumption which then remains speculative.
If trabeculae were “reinforced” in terms of increased min-
eralization of the existing structure with perhaps subsequent
thickening, one would wonder, howwould this be reflected by
TBS? In the context of TBS, because of the intrinsic value of
the experimental variogram, the trabecular thickening would
have only a limited influence on TBS parameters except when
the trabecular thickness would have been, prior to treatment,
thin enough to be negligible in the 2D projection. In this later
case, the thickening process would make the structure more
visible and would have a small impact [14]. This correlation
with trabecular thickness could be increased if other 3D
parameters would be taken into account into a model (e.g.,
at BV/TV and trabecular number constant). However, the
effect of anti-resorptive drugs on the bone quantity being
documented and the interpretation of stand-alone 3D param-
eters cannot be clearly stated other than a global positive
maintenance of the bone texture.Table 2 Mean annualized change in BMD and TBS for treated versus
untreated women
Variable Treated
women
Untreated
women
p
Mean follow-up (years) +3.6±1.1 +3.8±1.2 <0.001
Lumbar spine
BMD (% per year)
+1.9±1.8 % −0.4±1.6 % <0.001
Femoral neck
BMD (% per year)
+1.0±1.6 % −0.5±1.4 % <0.001
Total hip BMD
(% per year)
+1.1±1.3 % −0.6±1.2 % <0.001
Lumbar spine TBS
(% per year)
+0.2±1.9 % −0.3±2.0 % <0.001
Data are means ± SD
Statistical significance was set at p<0.01
Fig. 1 Annualized percent change in lumbar spine BMD and TBS in
treated and untreated women. Errors bars are 95 % confidence intervals
Table 1 Baseline demographic
and clinical characteristics
Statistical significance was set at
p<0.01
Variable Treated women(N0534) Untreated women(N01,150) p
Age (years) 66.1±8 62.2±7.9 <0.001
Height (cm) 160.4±6.3 161.4±6.5 0.620
Weight (kg) 63.6±10.9 68.5±12.8 0.164
BMI (kg/m2) 24.7±4 26.3±4.7 0.337
Lumbar spine TBS 1.21±0.12 1.26±0.11 <0.001
Lumbar spine BMD T-score −2.5±1 −1±1.2 <0.001
Neck T-score −2.1±0.7 −1.3±0.8 <0.001
Total hip T-score −1.9±0.8 −0.8±0.9 <0.001
BMD T-score minimum −2.9±0.8 −1.7±0.8 0.003
Prior major osteoporotic fracture 15.4 % 10.4 % 0.009
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Combining BMD and TBS could potentially provide a
better understanding of the overall effects of treatment at a
structural level. Ultimately, whether combining BMD and
TBS in clinical practice is warranted will require longitudi-
nal studies assessing not only how these two independent
markers of bone structure change over time, but also how
these changes correlate with fracture risk.
Our study is a first step towards establishing a possible
role for TBS in the monitoring of osteoporosis therapy.
However, to apply such parameters in the individual patient,
one needs to determine the least significant change (LSC)
and monitoring time interval (MTI) [37]. Our precision for
spine TBS (2.1 %) [23] is slightly worse than that for spine
BMD (1.7 %), while the average annual increase of TBS for
anti-resorptive therapy is much lower than that of BMD.
Therefore, the LSC and MTI for spine TBS would be
4.8 % and close to 10–15 years (corresponding values for
spine BMD 4.2 % and 2.5 years). The small increase in TBS
from anti-resorptive treatment limits the utility of TBS for
individual patient monitoring as only 12 % of treated sub-
jects had an increase in TBS that exceeded the LSC. This is
consistent with other observations that anti-resorptive thera-
py is expected to provide a “positive maintenance” of bone
micro-architecture rather than a major improvement in
micro-architecture [38]. Technically, since the TBS has been
shown to reflect treatment changes with osteoporosis-
targeted therapies [39–42] and to deteriorate significantly
over periods of time as short as 2 years in untreated patients,
it can be used to monitor the effectiveness of treatment once
the diagnosis of osteoporosis has been made. However, most
importantly, one still has to investigate how these changes
correlate with fracture risk. Potentially, one can also imagine
using TBS in conjunction with BMD and clinical risk factors
to select the most appropriate drugs as not all of them have
the same effect on bone texture [39–42], but most of them
show a similar BMD increase and fracture risk reduction.
However, this later statement is speculative and would re-
quire specific validation.
Our study has the advantages of a large cohort of older
women, a clinically relevant mean follow-up interval (aver-
age of 3.7 years), and a provincial pharmacy database to
assess drug initiation and adherence. One of the limitations
of our database is related to our inability to assess non-
pharmacological interventions (e.g., diet, vitamin D status,
exercise). Another limitation is that the follow-up interval is
not constant across all subjects, as in a clinical trial, so that
annualized percent change is difficult to compare against
previous clinical trials. However, the average change we
observed in lumbar spine BMD on treatment was +1.9 %
per year which, over the mean of 3.6 years of follow-up,
equates to a +6.8 % overall increase, which is similar to the
changes reported previously for clinical trials on major
bisphosphonates [36].
Conclusions
Based upon the results of a large study involving over 1,600
older women, lumbar spine TBS seems to be weakly re-
sponsive to anti-resorptive treatment and might be suitable
for monitoring bone texture in women untreated for osteo-
porosis. Although the treatment-related increase appears to
be considerably less than that observed for BMD, further
research delineating the value of TBS as an index of
treatment-related anti-fracture effect clearly is warranted.
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